Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling.

CONCLUSION: Our results unveil a novel mechanism by which miR-133a-3p inhibits bone metastasis of PCa, providing the evidence that miR-133a-3p may serve as a potential bone metastasis marker in PCa, and delivery of agomir-133a-3p may be an effective anti-bone metastasis therapeutic strategy in PCa.
PMID: 30021600 [PubMed - in process]

Source: Clinical Prostate Cancer - July 18, 2018 Category: Cancer & Oncology Authors: Tang Y, Pan J, Huang S, Peng X, Zou X, Luo Y, Ren D, Zhang X, Li R, He P, Wa Q Tags: J Exp Clin Cancer Res Source Type: research